CLDF Title
Home | Contact Us | Bookmark
NASH HCC
Centers of Educational Expertise  
Live CME Events Webcasts Slide Library Abstract Library CLDF 2019 Year in Review Conference Highlights
 
Back  
 
Reuters Health Information: FDA warns of death, liver injury risks from Intercept's drug Ocaliva

FDA warns of death, liver injury risks from Intercept's drug Ocaliva

Last Updated: 2017-09-21

By Reuters Staff

(Reuters) - The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc's drug Ocaliva (obeticholic acid) is being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

The U.S. drugmaker's shares fell 10.4 percent to $87.90 in afternoon trading following the news.

The FDA warning comes two weeks after Intercept gave healthcare providers prescribing information for Ocaliva and flagged reports of liver failure and deaths. (http://bit.ly/2xudehJ)

Ocaliva, approved last May, is used to treat primary biliary cholangitis (PBC), a rare, chronic liver disease that causes bile ducts in the liver to become inflamed, damaged and destroyed.

Nineteen deaths and 11 cases of serious liver injury were associated with the use of Ocaliva, the FDA said. Some patients were receiving higher doses of the drug, particularly due to a higher frequency of dosing than recommended in the label, the agency added. (http://bit.ly/2hiUvil)

"FDA's narrative about the high number of deaths and worsening of PBC cases strikes us as particularly concerning, and could tilt the FDA more toward a black box warning," Leerink analyst Joseph Schwartz said in a report to clients.

A black box warning is the strictest warning by the FDA that appears on a prescription drug's label, calling attention to serious or life-threatening risks of a drug.

However, RBC Capital Markets analysts said the risks flagged by the FDA were already known and included on the drug's label. The affected patients represent under 5 percent of the overall PBC population, limiting likely commercial impact to Intercept, they said.

In the quarter ended June 30, Intercept generated $30.4 million in worldwide sales from Ocaliva.

The New York-based company was reviewing the FDA's warning, Intercept said via email.

 
 
 
 
                               
 
HEPATITIS
HBV
HCV
HDV
 
 
HCC
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HRS
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
THROMBOCYTOPENIA
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2021 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.